Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

BDX vs BSX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$52.45B
5Y Perf.-2.7%
BSX
Boston Scientific Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$83.23B
5Y Perf.+47.4%

BDX vs BSX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BDX logoBDX
BSX logoBSX
IndustryMedical - Instruments & SuppliesMedical - Devices
Market Cap$52.45B$83.23B
Revenue (TTM)$21.92B$20.07B
Net Income (TTM)$1.76B$2.89B
Gross Margin45.8%69.0%
Operating Margin12.4%19.8%
Forward P/E11.6x16.6x
Total Debt$19.18B$12.42B
Cash & Equiv.$851M$2.04B

BDX vs BSXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BDX
BSX
StockMay 20May 26Return
Becton, Dickinson a… (BDX)10097.3-2.7%
Boston Scientific C… (BSX)100147.4+47.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: BDX vs BSX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BSX leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Becton, Dickinson and Company is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
BDX
Becton, Dickinson and Company
The Income Pick

BDX is the clearest fit if your priority is income & stability.

  • Dividend streak 1 yrs, beta 0.66, yield 2.9%
  • Lower P/E (11.6x vs 16.6x)
  • 2.9% yield; 1-year raise streak; the other pay no meaningful dividend
Best for: income & stability
BSX
Boston Scientific Corporation
The Growth Play

BSX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
  • 154.2% 10Y total return vs BDX's 72.9%
  • Lower volatility, beta 0.34, Low D/E 50.7%, current ratio 1.62x
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBSX logoBSX19.9% revenue growth vs BDX's 8.2%
ValueBDX logoBDXLower P/E (11.6x vs 16.6x)
Quality / MarginsBSX logoBSX14.4% margin vs BDX's 8.0%
Stability / SafetyBSX logoBSXBeta 0.34 vs BDX's 0.66, lower leverage
DividendsBDX logoBDX2.9% yield; 1-year raise streak; the other pay no meaningful dividend
Momentum (1Y)BDX logoBDX+45.3% vs BSX's -46.2%
Efficiency (ROA)BSX logoBSX6.9% ROA vs BDX's 3.2%, ROIC 8.8% vs 4.3%

BDX vs BSX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B
BSXBoston Scientific Corporation
FY 2025
Cardiovascular
66.0%$13.3B
MedSurg
34.0%$6.8B

BDX vs BSX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLBSXLAGGINGBDX

Income & Cash Flow (Last 12 Months)

BSX leads this category, winning 5 of 6 comparable metrics.

BDX and BSX operate at a comparable scale, with $21.9B and $20.1B in trailing revenue. BSX is the more profitable business, keeping 14.4% of every revenue dollar as net income compared to BDX's 8.0%. On growth, BSX holds the edge at +15.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBDX logoBDXBecton, Dickinson…BSX logoBSXBoston Scientific…
RevenueTrailing 12 months$21.9B$20.1B
EBITDAEarnings before interest/tax$5.2B$4.7B
Net IncomeAfter-tax profit$1.8B$2.9B
Free Cash FlowCash after capex$2.6B$3.6B
Gross MarginGross profit ÷ Revenue+45.8%+69.0%
Operating MarginEBIT ÷ Revenue+12.4%+19.8%
Net MarginNet income ÷ Revenue+8.0%+14.4%
FCF MarginFCF ÷ Revenue+12.0%+18.1%
Rev. Growth (YoY)Latest quarter vs prior year+1.6%+15.9%
EPS Growth (YoY)Latest quarter vs prior year+28.8%+18.5%
BSX leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

BDX leads this category, winning 6 of 6 comparable metrics.

At 24.8x trailing earnings, BDX trades at a 14% valuation discount to BSX's 28.9x P/E. On an enterprise value basis, BDX's 14.0x EV/EBITDA is more attractive than BSX's 25.1x.

MetricBDX logoBDXBecton, Dickinson…BSX logoBSXBoston Scientific…
Market CapShares × price$52.4B$83.2B
Enterprise ValueMkt cap + debt − cash$70.8B$93.6B
Trailing P/EPrice ÷ TTM EPS24.83x28.87x
Forward P/EPrice ÷ next-FY EPS est.11.59x16.58x
PEG RatioP/E ÷ EPS growth rate1.50x
EV / EBITDAEnterprise value multiple14.04x25.07x
Price / SalesMarket cap ÷ Revenue2.40x4.15x
Price / BookPrice ÷ Book value/share1.64x3.42x
Price / FCFMarket cap ÷ FCF19.64x22.75x
BDX leads this category, winning 6 of 6 comparable metrics.

Profitability & Efficiency

BSX leads this category, winning 8 of 8 comparable metrics.

BSX delivers a 12.4% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $7 for BDX. BSX carries lower financial leverage with a 0.51x debt-to-equity ratio, signaling a more conservative balance sheet compared to BDX's 0.76x.

MetricBDX logoBDXBecton, Dickinson…BSX logoBSXBoston Scientific…
ROE (TTM)Return on equity+6.9%+12.4%
ROA (TTM)Return on assets+3.2%+6.9%
ROICReturn on invested capital+4.3%+8.8%
ROCEReturn on capital employed+5.4%+11.1%
Piotroski ScoreFundamental quality 0–977
Debt / EquityFinancial leverage0.76x0.51x
Net DebtTotal debt minus cash$18.3B$10.4B
Cash & Equiv.Liquid assets$851M$2.0B
Total DebtShort + long-term debt$19.2B$12.4B
Interest CoverageEBIT ÷ Interest expense4.65x11.03x
BSX leads this category, winning 8 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

BSX leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in BSX five years ago would be worth $13,011 today (with dividends reinvested), compared to $11,037 for BDX. Over the past 12 months, BDX leads with a +45.3% total return vs BSX's -46.2%. The 3-year compound annual growth rate (CAGR) favors BSX at 1.8% vs BDX's -0.1% — a key indicator of consistent wealth creation.

MetricBDX logoBDXBecton, Dickinson…BSX logoBSXBoston Scientific…
YTD ReturnYear-to-date-4.9%-40.9%
1-Year ReturnPast 12 months+45.3%-46.2%
3-Year ReturnCumulative with dividends-0.4%+5.4%
5-Year ReturnCumulative with dividends+10.4%+30.1%
10-Year ReturnCumulative with dividends+72.9%+154.2%
CAGR (3Y)Annualised 3-year return-0.1%+1.8%
BSX leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — BDX and BSX each lead in 1 of 2 comparable metrics.

BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than BDX's 0.66 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BDX currently trades 70.4% from its 52-week high vs BSX's 51.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBDX logoBDXBecton, Dickinson…BSX logoBSXBoston Scientific…
Beta (5Y)Sensitivity to S&P 5000.66x0.34x
52-Week HighHighest price in past year$205.52$109.50
52-Week LowLowest price in past year$100.31$54.98
% of 52W HighCurrent price vs 52-week peak+70.4%+51.1%
RSI (14)Momentum oscillator 0–10030.533.1
Avg Volume (50D)Average daily shares traded2.5M15.3M
Evenly matched — BDX and BSX each lead in 1 of 2 comparable metrics.

Analyst Outlook

BDX leads this category, winning 1 of 1 comparable metric.

Wall Street rates BDX as "Buy" and BSX as "Buy". Consensus price targets imply 63.1% upside for BSX (target: $91) vs 19.4% for BDX (target: $173). BDX is the only dividend payer here at 2.88% yield — a key consideration for income-focused portfolios.

MetricBDX logoBDXBecton, Dickinson…BSX logoBSXBoston Scientific…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$172.85$91.33
# AnalystsCovering analysts3343
Dividend YieldAnnual dividend ÷ price+2.9%
Dividend StreakConsecutive years of raises10
Dividend / ShareAnnual DPS$4.17
Buyback YieldShare repurchases ÷ mkt cap+1.9%0.0%
BDX leads this category, winning 1 of 1 comparable metric.
Key Takeaway

BSX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BDX leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallBoston Scientific Corporati… (BSX)Leads 3 of 6 categories
Loading custom metrics...

BDX vs BSX: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is BDX or BSX a better buy right now?

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus 8. 2% for Becton, Dickinson and Company (BDX). Becton, Dickinson and Company (BDX) offers the better valuation at 24. 8x trailing P/E (11. 6x forward), making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BDX or BSX?

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 24.

8x versus Boston Scientific Corporation at 28. 9x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 11. 6x.

03

Which is the better long-term investment — BDX or BSX?

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +30.

1%, compared to +10. 4% for Becton, Dickinson and Company (BDX). Over 10 years, the gap is even starker: BSX returned +154. 2% versus BDX's +72. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BDX or BSX?

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Becton, Dickinson and Company's 0. 66β — meaning BDX is approximately 91% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 76% for Becton, Dickinson and Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — BDX or BSX?

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus 8. 2% for Becton, Dickinson and Company (BDX). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BDX or BSX?

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus 7. 7% for Becton, Dickinson and Company — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus 11. 8% for BDX. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BDX or BSX more undervalued right now?

On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 11.

6x forward P/E versus 16. 6x for Boston Scientific Corporation — 5. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 63. 1% to $91. 33.

08

Which pays a better dividend — BDX or BSX?

In this comparison, BDX (2.

9% yield) pays a dividend. BSX does not pay a meaningful dividend and should not be held primarily for income.

09

Is BDX or BSX better for a retirement portfolio?

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 9% yield). Both have compounded well over 10 years (BDX: +72. 9%, BSX: +154. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BDX and BSX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BDX is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. BDX pays a dividend while BSX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.1%
Run This Screen
Stocks Like

BSX

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 8%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform BDX and BSX on the metrics below

Revenue Growth>
%
(BDX: 1.6% · BSX: 15.9%)
Net Margin>
%
(BDX: 8.0% · BSX: 14.4%)
P/E Ratio<
x
(BDX: 24.8x · BSX: 28.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.